Please wait while the formulary information is being retrieved.
PROVERA (MEDROXYPROGESTERONE ACETATE)
- Abnormal uterine bleeding due to hormonal imbalance
- Endometrial hyperplasia prevention
- Secondary amenorrhea
10 mg tablet
- 1 tablet (10 mg) by oral route once daily
2.5 mg tablet
- 2 tablets (5 mg) by oral route once daily
5 mg tablet
- 1 tablet (5 mg) by oral route once daily
medroxyprogesterone 10 mg tablet
- 1 tablet (10 mg) by oral route once daily
medroxyprogesterone 2.5 mg tablet
- 2 tablets (5 mg) by oral route once daily
medroxyprogesterone 5 mg tablet
- 1 tablet (5 mg) by oral route once daily
Abnormal uterine bleeding due to hormonal imbalance
- 2 tablets (5 mg) by oral route once daily
- 1 tablet (5 mg) by oral route once daily
- 2 tablets (5 mg) by oral route once daily for 5 days
- 2 tablets (5 mg) by oral route once daily for 10 days
- 1 tablet (5 mg) by oral route once daily for 5 days
- 1 tablet (5 mg) by oral route once daily for 10 days
- 1 tablet (10 mg) by oral route once daily
- 2 tablets (10 mg) by oral route once daily for 5 days
- 2 tablets (10 mg) by oral route once daily for 10 days
- 1 tablet (10 mg) by oral route once daily for 5 days
- 1 tablet (10 mg) by oral route once daily for 10 days
- 2 tablets (10 mg) by oral route once daily
Endogenous estrogen production test
- 1 tablet (10 mg) by oral route once daily
- 2 tablets (10 mg) by oral route once daily for 5 days
- 2 tablets (10 mg) by oral route once daily for 10 days
- 1 tablet (10 mg) by oral route once daily for 5 days
- 1 tablet (10 mg) by oral route once daily for 10 days
- 2 tablets (10 mg) by oral route once daily
Endometrial hyperplasia prevention
- 2 tablets (5 mg) by oral route once daily
- 1 tablet (5 mg) by oral route once daily
- 1 tablet (5 mg) by oral route once daily for 12 days
- 1 tablet (5 mg) by oral route once daily for 14 days
- 2 tablets (5 mg) by oral route once daily for 12 days
- 2 tablets (5 mg) by oral route once daily for 14 days
- 1 tablet (10 mg) by oral route once daily for 12 days
- 1 tablet (10 mg) by oral route once daily for 14 days
- 2 tablets (10 mg) by oral route once daily for 12 days
- 2 tablets (10 mg) by oral route once daily for 14 days
- 1 tablet (10 mg) by oral route once daily
- 2 tablets (10 mg) by oral route once daily
Secondary amenorrhea
- 2 tablets (5 mg) by oral route once daily
- 1 tablet (5 mg) by oral route once daily
- 2 tablets (5 mg) by oral route once daily for 5 days
- 2 tablets (5 mg) by oral route once daily for 10 days
- 1 tablet (5 mg) by oral route once daily for 5 days
- 1 tablet (5 mg) by oral route once daily for 10 days
- 1 tablet (10 mg) by oral route once daily
- 2 tablets (10 mg) by oral route once daily for 5 days
- 2 tablets (10 mg) by oral route once daily for 10 days
- 1 tablet (10 mg) by oral route once daily for 5 days
- 1 tablet (10 mg) by oral route once daily for 10 days
- 2 tablets (10 mg) by oral route once daily
- None
Contraindicated
- None
Severe
Moderate
- None
- Carcinoma of breast
- Cerebrovascular disorder
- Porphyria
- Predisposition to thrombosis
- Severe hepatic disease
- Thromboembolic disorder
- Thrombophlebitis
Contraindicated
- Osteopenia
- Osteoporosis
Severe
Moderate
- Breast fibroadenosis
- Depression
- Diabetes mellitus
- Edema
- Family history of malignant tumor of breast
- Hyperlipidemia
- Hypertension
- Weight gain
PROVERA (MEDROXYPROGESTERONE ACETATE)
- Abnormal uterine bleeding due to hormonal imbalance
- Endometrial hyperplasia prevention
- Secondary amenorrhea
- Abdominal distension
- Abnormal vaginal bleeding
- Irregular menstrual periods
- Appetite changes
- Edema
- Fatigue
- Headache disorder
- Myalgias
- Vaginitis
- Weight loss
More Frequent
Severe
Less Severe
- None
- Dizziness
- Dyspepsia
- Hypertonia
- Irritability
- Vaginal discharge
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Anaphylaxis
- Angioedema
- Back pain
- Chest pain
- Cystitis
- Depression
- Ectopic pregnancy
- Erythema multiforme
- Erythema nodosum
- Galactorrhea not associated with childbirth
- Hepatitis
- Hypersensitivity drug reaction
- Malignant neoplasm of the ovary
- Menorrhagia
- Obstructive hyperbilirubinemia
- Optic neuritis
- Ovarian cyst
- Pancreatitis
- Pruritus of skin
- Pulmonary thromboembolism
- Retinal thrombosis
- Skin rash
- Thromboembolic disorder
- Thrombophlebitis
Less Severe
- Acne vulgaris
- Alopecia
- Amenorrhea
- Body fluid retention
- Cervical discharge
- Chloasma
- Constipation
- Drowsy
- Erosion of cervix
- Fever
- Hirsutism
- Hyperglycemia
- Insomnia
- Limb pain
- Mastalgia
- Migraine
- Nausea
- Nervousness
- Urticaria
- Weight gain
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Medroxyprogesterone (Oral)
Safety and efficacy not established.
- 1 Day – 18 Years
- Safety and efficacy not established.
Medroxyprogesterone
- Severity Level:
2
- Additional Notes: Available data suggest little or no known risk for developmental toxicity
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
Medroxyprogesterone
Human data indicate no known adverse effect on nursing infant
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Excreted | No adverse effect | Human data indicate no known adverse effect on nursing infant |
Contraindicated
None
Precaution Exists
Medroxyprogesterone Ac
Neuro/Psych-The Women's Health Initiative Memory Study demonstrated an increased relative risk (2.05, 95% CI) of probable dementia in the elderly when used in combination with estrogens.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | Y | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- Medroxyprogesterone is sometimes used with another medication (a type of estrogen) as combination hormone replacement therapy (HRT) in women after menopause. Combination HRT can rarely cause very serious side effects such as heart disease (e.g., heart attacks), stroke, serious blood clots (e.g., in the lungs and legs), dementia, and breast cancer. Some of these risks appear to depend on the length of treatment and other factors.<br /><br />Therefore, combination HRT should be used for the shortest possible length of time at the lowest effective dose so you can obtain the benefits and minimize the chance of serious side effects from long-term treatment. Combination HRT should not be used to prevent heart disease or dementia. Discuss the risks and benefits of treatment and your personal health history with your doctor.<br /><br />If you take combination HRT, check with your doctor regularly (e.g., every 3-6 months) to see if you still need to take it. If you use this medication for an extended period, you should have a complete physical exam at regular intervals (e.g., once a year) or as directed by your doctor. See Notes section.
| Abnormal uterine bleeding due to hormonal imbalance | |
| N92.4 | Excessive bleeding in the premenopausal period |
| N92.5 | Other specified irregular menstruation |
| N92.6 | Irregular menstruation, unspecified |
| N93.8 | Other specified abnormal uterine and vaginal bleeding |
| N93.9 | Abnormal uterine and vaginal bleeding, unspecified |
| N95.0 | Postmenopausal bleeding |
| Secondary amenorrhea | |
| N91.1 | Secondary amenorrhea |
| N91.2 | Amenorrhea, unspecified |
| 0-9 | A-Z |
|---|---|
| N91.1 | Secondary amenorrhea |
| N91.2 | Amenorrhea, unspecified |
| N92.4 | Excessive bleeding in the premenopausal period |
| N92.5 | Other specified irregular menstruation |
| N92.6 | Irregular menstruation, unspecified |
| N93.8 | Other specified abnormal uterine and vaginal bleeding |
| N93.9 | Abnormal uterine and vaginal bleeding, unspecified |
| N95.0 | Postmenopausal bleeding |
Formulary Reference Tool